Entries by Thomas Gabrielczyk

Bringing virotherapy forward

Whether it´s oncolytic viruses or vectors for cancer therapy or modern vaccines, the demand for development, production or filling capacities is rising rapidly. To keep pace with this rise in customer demand, Vibalogics, which recently became part of the Recipharm Group, is investing around US$50m in the expansion of its Cuxhaven site by the end of the year, and even more in the US site near Boston.

Non-viral is better

Immunogenicity and limited gene transfer capacity can negatively affect the outcome of cell and gene therapies. European Biotechnology magazine spoke to Dr Dimitrios Laurin Wagner, Berlin Center for Advanced Therapies (BeCAT) and Gene Editing for Cell Therapy group leader at Charité, on new approaches that promise to overcome some limitations of current virus-based gene therapies.

Transformative innovation in drug development

The technological and pharmacological advances lead to an increase in the ­number of molecules for R&D that are challenging and difficult to manufacture. To improve ­clinical success, pharma and biotech companies are seeking innovative ways to accelerate progress and ­reduce scientific, economic, and delivery risks.